Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quality Improvement | 6 | 2022 | 413 | 1.430 |
Why?
|
| Regional Medical Programs | 1 | 2020 | 22 | 0.750 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 27 | 0.730 |
Why?
|
| Hospital Administration | 1 | 2020 | 43 | 0.730 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 124 | 0.580 |
Why?
|
| Postoperative Complications | 2 | 2020 | 1615 | 0.520 |
Why?
|
| Analgesics, Opioid | 4 | 2022 | 498 | 0.410 |
Why?
|
| Treatment Outcome | 2 | 2022 | 7029 | 0.360 |
Why?
|
| Breast Neoplasms | 5 | 2021 | 1536 | 0.350 |
Why?
|
| Pain, Postoperative | 3 | 2022 | 214 | 0.340 |
Why?
|
| Hospitals | 2 | 2022 | 265 | 0.330 |
Why?
|
| Tonsillectomy | 2 | 2021 | 69 | 0.330 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 65 | 0.320 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2021 | 62 | 0.320 |
Why?
|
| General Surgery | 1 | 2009 | 95 | 0.300 |
Why?
|
| Rural Health Services | 1 | 2009 | 101 | 0.300 |
Why?
|
| Schools, Medical | 1 | 2009 | 157 | 0.300 |
Why?
|
| Opioid-Related Disorders | 2 | 2022 | 298 | 0.290 |
Why?
|
| South Carolina | 5 | 2021 | 2752 | 0.290 |
Why?
|
| Polymerase Chain Reaction | 2 | 1998 | 492 | 0.290 |
Why?
|
| Retrospective Studies | 8 | 2022 | 7277 | 0.270 |
Why?
|
| Internship and Residency | 1 | 2009 | 596 | 0.220 |
Why?
|
| Adolescent | 4 | 2022 | 8912 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 33 | 0.190 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 17 | 0.190 |
Why?
|
| Lymphatic Metastasis | 2 | 1998 | 274 | 0.180 |
Why?
|
| Young Adult | 2 | 2022 | 5717 | 0.180 |
Why?
|
| Lymph Nodes | 2 | 1998 | 258 | 0.180 |
Why?
|
| Aged | 5 | 2022 | 14862 | 0.170 |
Why?
|
| Humans | 15 | 2022 | 68618 | 0.160 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 135 | 0.160 |
Why?
|
| Middle Aged | 7 | 2022 | 21147 | 0.160 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 27 | 0.160 |
Why?
|
| Herniorrhaphy | 1 | 2019 | 38 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2022 | 504 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 378 | 0.150 |
Why?
|
| Surgeons | 1 | 2019 | 68 | 0.150 |
Why?
|
| Colon | 1 | 2018 | 168 | 0.150 |
Why?
|
| Adult | 5 | 2022 | 21403 | 0.140 |
Why?
|
| Iridium Radioisotopes | 1 | 1996 | 11 | 0.140 |
Why?
|
| Carcinoma, Lobular | 1 | 1996 | 20 | 0.140 |
Why?
|
| Mastectomy, Segmental | 3 | 2021 | 64 | 0.130 |
Why?
|
| Brachytherapy | 1 | 1996 | 79 | 0.130 |
Why?
|
| United States | 3 | 2022 | 7367 | 0.130 |
Why?
|
| Female | 11 | 2022 | 38074 | 0.120 |
Why?
|
| Bariatric Surgery | 1 | 2015 | 90 | 0.120 |
Why?
|
| Forecasting | 1 | 2015 | 277 | 0.120 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 172 | 0.110 |
Why?
|
| Diverticulitis, Colonic | 1 | 2013 | 10 | 0.110 |
Why?
|
| Cutaneous Fistula | 1 | 2013 | 11 | 0.110 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 21 | 0.110 |
Why?
|
| Intestinal Fistula | 1 | 2013 | 26 | 0.110 |
Why?
|
| Intestinal Perforation | 1 | 2013 | 35 | 0.110 |
Why?
|
| Neoplasm Staging | 3 | 1998 | 800 | 0.090 |
Why?
|
| Male | 7 | 2022 | 37321 | 0.090 |
Why?
|
| Prognosis | 3 | 2021 | 2093 | 0.080 |
Why?
|
| Tennessee | 1 | 2009 | 11 | 0.080 |
Why?
|
| Axilla | 2 | 1998 | 36 | 0.080 |
Why?
|
| Reoperation | 2 | 2021 | 467 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2009 | 248 | 0.080 |
Why?
|
| Child | 3 | 2022 | 6405 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 2891 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 3187 | 0.050 |
Why?
|
| Appendectomy | 1 | 2022 | 47 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| Mastectomy | 1 | 2021 | 57 | 0.050 |
Why?
|
| Waste Management | 1 | 2020 | 11 | 0.050 |
Why?
|
| Aftercare | 1 | 2021 | 114 | 0.040 |
Why?
|
| Thymoma | 1 | 1999 | 14 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 1999 | 17 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 63 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 1999 | 75 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 1999 | 61 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2019 | 33 | 0.040 |
Why?
|
| Epitopes | 1 | 1999 | 146 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1054 | 0.040 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1998 | 11 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 132 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 79 | 0.040 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1998 | 6 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 294 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 1998 | 12 | 0.040 |
Why?
|
| Keratins | 1 | 1998 | 48 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 1998 | 91 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1603 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 425 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 397 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 1999 | 483 | 0.030 |
Why?
|
| Esthetics | 1 | 1996 | 18 | 0.030 |
Why?
|
| Biopsy | 1 | 1998 | 540 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 504 | 0.030 |
Why?
|
| Edema | 1 | 1996 | 66 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1996 | 129 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 1996 | 125 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 349 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 130 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 508 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1998 | 1753 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 1996 | 951 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1996 | 446 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 1998 | 1851 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 978 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1140 | 0.020 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1999 | 22 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 1999 | 23 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1999 | 33 | 0.010 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1999 | 42 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 160 | 0.010 |
Why?
|
| Th1 Cells | 1 | 1999 | 101 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 301 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1999 | 230 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1999 | 241 | 0.010 |
Why?
|
| Vaccination | 1 | 1999 | 189 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 1083 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1999 | 1447 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1999 | 370 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1999 | 2791 | 0.010 |
Why?
|
| Mice | 1 | 1999 | 8474 | 0.000 |
Why?
|
| Animals | 1 | 1999 | 20881 | 0.000 |
Why?
|